Glenn Jaffe, MD
Ophthalmology · Durham, NCNPI 1255415311
Payments from drug & device makers
Across 504 payments — averaging $76,410 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$29.2M
- Roche TCRC, Inc.$7.1M
- F. Hoffmann-la Roche AG$1.5M
- Hoffmann-la Roche Limited$221K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$121K
- PTC Therapeutics, Inc.$112K
- plus $209K from 21 others
Across 23 payments — averaging $1634.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$22K
- Novartis Pharma AG$10K
- Novartis$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 218 | $29,217,307 |
| Roche TCRC, Inc. | 129 | $7,125,835 |
| F. Hoffmann-la Roche AG | 41 | $1,505,224 |
| Hoffmann-la Roche Limited | 9 | $221,206 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $120,616 |
| PTC Therapeutics, Inc. | 16 | $111,731 |
| Regeneron | 9 | $90,586 |
| Neurotech Pharmaceuticals, Inc. | 4 | $44,873 |
| Bausch Health US, LLC | 8 | $16,596 |
| Bausch & Lomb Americas Inc. | 10 | $15,636 |
| Eyepoint US, Inc. | 18 | $14,597 |
| Ocular Therapeutix, Inc. | 12 | $13,006 |
| Thrombogenics, Inc. | 1 | $10,949 |
| Hexal AG | 1 | $475 |
| Alimera Sciences, Inc. | 4 | $403 |
| Regeneron Healthcare Solutions, Inc. | 2 | $245 |
| Apellis Pharmaceuticals, Inc. | 2 | $225 |
| Heidelberg Engineering, Inc. | 1 | $205 |
| Coherus Oncology, Inc. | 2 | $168 |
| Dutch Ophthalmic, USA | 1 | $150 |
| Alcon Research LLC | 1 | $148 |
| Carl Zeiss Meditec, Inc. | 1 | $142 |
| ANI Pharmaceuticals, Inc. | 1 | $122 |
| AbbVie | 1 | $103 |
| Topcon Healthcare, Inc. | 2 | $86 |
| Biocryst Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $23 |
How this compares
$38,510,681 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Durham
- Lejla VajzovicDurham$7.5M
- Majda HadziahmetovicDurham$2.4M
- Julie WoodwardDurham$1M
- Terry KimDurham$605K
- Anthony KuoDurham$392K
- Leon HerndonDurham$350K
- Robin VannDurham$213K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Laura EnyediDurham$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.